Bicycle Therapeutics (NASDAQ:BCYC) Announces Earnings Results, Beats Estimates By $0.63 EPS

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($1.25) by $0.63, Briefing.com reports. Bicycle Therapeutics had a negative return on equity of 57.80% and a negative net margin of 669.72%. The business had revenue of $19.53 million during the quarter, compared to the consensus estimate of $6.06 million. The company's revenue for the quarter was up 298.9% on a year-over-year basis.

Bicycle Therapeutics Trading Down 0.4 %

Shares of NASDAQ:BCYC traded down $0.11 during midday trading on Friday, hitting $24.58. 324,430 shares of the stock were exchanged, compared to its average volume of 373,722. The stock has a market capitalization of $738.38 million, a price-to-earnings ratio of -4.79 and a beta of 0.90. The company has a debt-to-equity ratio of 0.08, a quick ratio of 8.08 and a current ratio of 8.08. The business's 50-day moving average price is $24.03 and its 200 day moving average price is $19.44. Bicycle Therapeutics has a 12 month low of $12.54 and a 12 month high of $28.91.

Analysts Set New Price Targets

A number of research firms have issued reports on BCYC. Needham & Company LLC reiterated a "buy" rating and issued a $43.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, April 10th. Canaccord Genuity Group reiterated a "buy" rating and issued a $60.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, February 21st. Finally, HC Wainwright reiterated a "buy" rating and issued a $55.00 target price on shares of Bicycle Therapeutics in a research report on Friday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $46.86.

Insider Transactions at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 3,158 shares of the company's stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $23.81, for a total value of $75,191.98. Following the sale, the chief executive officer now directly owns 387,270 shares in the company, valued at $9,220,898.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 5,312 shares of company stock worth $126,139. Insiders own 10.20% of the company's stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.